GSK’s multiple myeloma therapy Blenrep has taken a step closer to a remarkable comeback, with new Phase III data confirming that the antibody-drug conjugate (ADC) significantly extended overall survival (OS) in relapsed/refractory multiple myeloma patients compared with standard-of-care.
The topline result from the DREAMM-7 study unveiled on 14 November showed that Blenrep (belantamab mafodotin) in combination with bortezomib...